Cantor Fitzgerald Reiterates “Overweight” Rating for Septerna (NASDAQ:SEPN)

Septerna (NASDAQ:SEPN)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a note issued to investors on Tuesday,Benzinga reports. They currently have a $50.00 target price on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 341.70% from the stock’s previous close.

SEPN has been the subject of a number of other reports. Wells Fargo & Company began coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 price target for the company. JPMorgan Chase & Co. began coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price target for the company. Finally, TD Cowen assumed coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued a “buy” rating for the company.

Septerna Price Performance

SEPN opened at $11.32 on Tuesday. Septerna has a 1-year low of $10.34 and a 1-year high of $28.99. The stock has a 50 day moving average price of $19.87.

Hedge Funds Weigh In On Septerna

A number of hedge funds and other institutional investors have recently modified their holdings of SEPN. SG Americas Securities LLC bought a new position in shares of Septerna during the fourth quarter worth $185,000. Rhumbline Advisers bought a new position in shares of Septerna during the fourth quarter worth $458,000. New York State Common Retirement Fund bought a new position in shares of Septerna during the fourth quarter worth $32,000. Bank of New York Mellon Corp bought a new position in shares of Septerna during the fourth quarter worth $872,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in Septerna during the fourth quarter valued at $3,197,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.